140 related articles for article (PubMed ID: 36840023)
1. Acceptability, Swallowability, Palatability, and Safety of Multiple Film-Coated Mini-Tablets in Children Aged ≥2-<7 Years: Results of an Open-Label Randomised Study.
Münch J; Kloft C; Farhan M; Fishman V; Leng S; Bosse HM; Klingmann V
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840023
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over Study.
Münch J; Sessler I; Bosse HM; Wargenau M; Dreesen JD; Loforese G; Webb NJA; Sivasubramanian R; Reidemeister S; Lustenberger P; Klingmann V
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376177
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of small-sized oblong tablets in comparison to syrup and mini-tablets in infants and toddlers: A randomized controlled trial.
Münch J; Meissner T; Mayatepek E; Wargenau M; Breitkreutz J; Bosse HM; Klingmann V
Eur J Pharm Biopharm; 2021 Sep; 166():126-134. PubMed ID: 34153451
[TBL] [Abstract][Full Text] [Related]
4. Acceptability of multiple coated mini-tablets in comparison to syrup in infants and toddlers: a randomised controlled study.
Klingmann V; Hinder M; Langenickel TH; Chen F; Khder Y; Breitkreutz J; Bosse HM
Arch Dis Child; 2023 Sep; 108(9):730-735. PubMed ID: 36963813
[TBL] [Abstract][Full Text] [Related]
5. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
Freerks L; Sommerfeldt J; Löper PC; Klein S
Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
[TBL] [Abstract][Full Text] [Related]
6. Young patients' involvement in a composite endpoint method development on acceptability for paediatric oral dosage forms.
Reidemeister S; Nafria Escalera B; Marín D; Balayla J; Klingmann I; Klingmann V
Res Involv Engagem; 2023 Nov; 9(1):108. PubMed ID: 38031172
[TBL] [Abstract][Full Text] [Related]
7. Sensory aspects of acceptability of bitter-flavoured 7.5 mm film-coated tablets in adults, preschool and school children.
Hofmanová JK; Mason J; Batchelor HK
Int J Pharm; 2020 Jul; 585():119511. PubMed ID: 32522503
[TBL] [Abstract][Full Text] [Related]
8. Acceptability of Uncoated Mini-Tablets in Neonates--A Randomized Controlled Trial.
Klingmann V; Seitz A; Meissner T; Breitkreutz J; Moeltner A; Bosse HM
J Pediatr; 2015 Oct; 167(4):893-896.e2. PubMed ID: 26259675
[TBL] [Abstract][Full Text] [Related]
9. Creating Acceptable Tablets 3D (CAT 3D): A Feasibility Study to Evaluate the Acceptability of 3D Printed Tablets in Children and Young People.
Bracken L; Habashy R; McDonough E; Wilson F; Shakeshaft J; Ohia U; Garcia-Sorribes T; Isreb A; Alhnan MA; Peak M
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335892
[TBL] [Abstract][Full Text] [Related]
10. Developing methodology to evaluate the oral sensory features of pharmaceutical tablet coatings.
Hofmanová JK; Rajabi-Siahboomi A; Haque S; Mason J; Teckoe J; To D; Batchelor HK
Int J Pharm; 2019 May; 562():212-217. PubMed ID: 30910634
[TBL] [Abstract][Full Text] [Related]
11. A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population.
Wargenau M; Reidemeister S; Klingmann I; Klingmann V
Ther Innov Regul Sci; 2022 Nov; 56(6):903-909. PubMed ID: 35471561
[TBL] [Abstract][Full Text] [Related]
12. A novel soft robotic pediatric in vitro swallowing device to gain insights into the swallowability of mini-tablets.
Lavoisier A; Avila-Sierra A; Timpe C; Kuehl P; Wagner L; Tournier C; Ramaioli M
Int J Pharm; 2022 Dec; 629():122369. PubMed ID: 36351507
[TBL] [Abstract][Full Text] [Related]
13. Acceptability of Mini-Tablets in Young Children: Results from Three Prospective Cross-over Studies.
Klingmann V
AAPS PharmSciTech; 2017 Feb; 18(2):263-266. PubMed ID: 27714698
[TBL] [Abstract][Full Text] [Related]
14. Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable tablets (CAT)).
Bracken L; McDonough E; Ashleigh S; Wilson F; Shakeshaft J; Ohia U; Mistry P; Jones H; Kanji N; Liu F; Peak M
BMJ Open; 2020 Oct; 10(10):e036508. PubMed ID: 33039988
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.
Kakuda TN; Berckmans C; De Smedt G; Leemans R; Leopold L; Peeters M; Nijs S; Vyncke V; van Solingen-Ristea R; Hoetelmans RM
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):725-37. PubMed ID: 23924679
[TBL] [Abstract][Full Text] [Related]
16. Paediatric solid oral dosage forms for combination products: Improving in vitro swallowability of minitablets using binary mixtures with pellets.
Avila-Sierra A; Lavoisier A; Timpe C; Kuehl P; Wagner L; Tournier C; Ramaioli M
Eur J Pharm Sci; 2023 Aug; 187():106471. PubMed ID: 37210000
[TBL] [Abstract][Full Text] [Related]
17. Influence of Solid Oral Dosage Form Characteristics on Swallowability, Visual Perception, and Handling in Older Adults.
Hummler H; Page S; Stillhart C; Meilicke L; Grimm M; Mannaa M; Gollasch M; Weitschies W
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111799
[TBL] [Abstract][Full Text] [Related]
18. Multi-Analytical Framework to Assess the In Vitro Swallowability of Solid Oral Dosage Forms Targeting Patient Acceptability and Adherence.
Ershad AL; Rajabi-Siahboomi A; Missaghi S; Kirby D; Mohammed AR
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33808875
[TBL] [Abstract][Full Text] [Related]
19. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers.
Jakate A; McNamee B; Burkindine D
Clin Pharmacol; 2019; 11():93-101. PubMed ID: 31372067
[No Abstract] [Full Text] [Related]
[Next] [New Search]
